

Please remember:

- BLINCYTO may cause neurological events including:
 - » Shaking (tremor)
 - » Confusion
 - » Disturbances of brain function (encephalopathy)
 - » Difficulty in communicating (aphasia)
 - » Seizure (convulsion)



Please call your doctor or nurse immediately if you experience any of these symptoms



Please travel home safely and do not drive or operate moving vehicles/heavy machinery, or engage in hazardous activities whilst receiving BLINCYTO

- If there are problems or unexpected stopping of the infusion pump, call your doctor or nurse immediately. Please don't try to fix any issues yourself.

Version 3.0 Approved: October 2021

Patient Card



Please show this card to all emergency and healthcare providers

**Information about
BLINCYTO[®]▼(blinatumomab)**

My name is _____

In Case of Emergency (ICE) contact

I am being treated with BLINCYTO,
a treatment for B-precursor acute
lymphoblastic leukaemia, which can
lower my immune system.

I started treatment on _____

Before providing any treatment, please call my prescribing physician at the number below. If any medical evaluations are undertaken, please provide copies of all medical records, including any treatments and/or test results, to the doctor(s) named below.

	Name	Hospital	City	Phone Number
Haematologist				
Oncologist				
Haematology Nurse				

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441 or Freephone 1800 535 160.